Note 5 - Fair Value Measurements - Roll-forward of the Carrying Value of the Contingent Consideration (Details) - Contingent Consideration [Member] - USD ($) $ in Thousands |
12 Months Ended | |
---|---|---|
Dec. 31, 2016 |
Dec. 31, 2015 |
|
Balance | $ 18,549 | $ 26,542 |
Accretion | 1,300 | 0 |
Payments | (475) | 0 |
Adjustment to fair value | (11,860) | (7,993) |
Balance | 7,514 | 18,549 |
Asuragen [Member] | ||
Balance | 4,628 | 4,476 |
Accretion | 325 | 0 |
Payments | (475) | 0 |
Adjustment to fair value | (2,933) | 152 |
Balance | 1,545 | 4,628 |
RedPath [Member] | ||
Balance | 13,921 | 22,066 |
Accretion | 975 | 0 |
Payments | 0 | |
Adjustment to fair value | (8,927) | (8,145) |
Balance | $ 5,969 | $ 13,921 |
X | ||||||||||
- Definition Amount of accretion of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. No definition available.
|
X | ||||||||||
- Definition Amount of gain (loss) recognized on the income statement for financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|